After successful treatment with imatinib and/or other BCR::ABL1 inhibitors leading to major or complete molecular responses, the numbers of CD203c+ basophils decreased substantially in our CML patients compared to pre-treatment values. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.